[go: up one dir, main page]

MX2023002984A - Nuevos anticuerpos anti-a2ap y usos de los mismos. - Google Patents

Nuevos anticuerpos anti-a2ap y usos de los mismos.

Info

Publication number
MX2023002984A
MX2023002984A MX2023002984A MX2023002984A MX2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A MX 2023002984 A MX2023002984 A MX 2023002984A
Authority
MX
Mexico
Prior art keywords
a2ap
antibodies
new anti
antigen
binding fragment
Prior art date
Application number
MX2023002984A
Other languages
English (en)
Inventor
Andreas Wilmen
Stefan Heitmeier
Ernst Weber
Hannah Jörissen
Cindy Schulenburg
Julia Glunz
Melanie Fischer
Christoph Thiel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2023002984A publication Critical patent/MX2023002984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une a A2AP humana. El anticuerpo aislado o fragmento de unión a antígeno según la presente invención i) reacciona de forma cruzada con A2AP de conejo y/o cynomolgus, ii) no inhibe la actividad de la plasmina humana, y iii) aumenta la lisis del coágulo mediada por plasmina en presencia de A2AP.
MX2023002984A 2020-09-15 2021-09-13 Nuevos anticuerpos anti-a2ap y usos de los mismos. MX2023002984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196259 2020-09-15
PCT/EP2021/075038 WO2022058261A2 (en) 2020-09-15 2021-09-13 Novel anti-a2ap antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002984A true MX2023002984A (es) 2023-04-10

Family

ID=72521424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002984A MX2023002984A (es) 2020-09-15 2021-09-13 Nuevos anticuerpos anti-a2ap y usos de los mismos.

Country Status (13)

Country Link
US (3) US20240010750A1 (es)
EP (1) EP4214241A2 (es)
JP (2) JP7454106B2 (es)
KR (1) KR20230069171A (es)
CN (1) CN116249719A (es)
AR (1) AR123523A1 (es)
AU (1) AU2021343834A1 (es)
CA (1) CA3194792A1 (es)
IL (1) IL301307B2 (es)
MX (1) MX2023002984A (es)
PE (1) PE20240214A1 (es)
WO (1) WO2022058261A2 (es)
ZA (1) ZA202405587B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240010750A1 (en) * 2020-09-15 2024-01-11 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6114506A (en) * 1996-09-20 2000-09-05 General Hospital Corporation Composition and method for enhancing fibrinolysis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN101720368A (zh) 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
US20240010750A1 (en) * 2020-09-15 2024-01-11 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof

Also Published As

Publication number Publication date
IL301307B2 (en) 2025-09-01
AU2021343834A1 (en) 2023-04-13
CN116249719A (zh) 2023-06-09
US20240034810A1 (en) 2024-02-01
JP2024063234A (ja) 2024-05-10
TW202227505A (zh) 2022-07-16
JP7454106B2 (ja) 2024-03-21
KR20230069171A (ko) 2023-05-18
EP4214241A2 (en) 2023-07-26
US20240166766A1 (en) 2024-05-23
WO2022058261A3 (en) 2022-06-16
US12215168B2 (en) 2025-02-04
CA3194792A1 (en) 2022-03-24
WO2022058261A2 (en) 2022-03-24
IL301307B1 (en) 2025-05-01
JP2023541179A (ja) 2023-09-28
ZA202405587B (en) 2025-05-28
IL301307A (en) 2023-05-01
US20240010750A1 (en) 2024-01-11
AR123523A1 (es) 2022-12-14
BR112023002800A2 (pt) 2023-03-21
PE20240214A1 (es) 2024-02-16

Similar Documents

Publication Publication Date Title
ECSP20076683A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CL2025000403A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2019000659A1 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo.
MX2020006213A (es) Anticuerpos anti-trem2 y metodos relacionados.
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
PE20191106A1 (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
DOP2019000064A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
DOP2023000214A (es) Conjugados de anticuerpo anti-nectina-4 y exatecano
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
MX2021000889A (es) Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
AR114274A1 (es) Anticuerpos dirigidos contra pla2-gib y los usos de los mismos
MX2022007353A (es) Anticuerpos novedosos ddr1 y sus usos.
CL2024003668A1 (es) Anticuerpo anti-fcrn o fragmento de unión a antígeno del mismo con estabilidad mejorada.
CO2023004251A2 (es) Anticuerpo que se une a vegf-a y ang2, y métodos de uso
CL2024003486A1 (es) Anticuerpo anti-b7h3 y usos del mismo
MX2023002984A (es) Nuevos anticuerpos anti-a2ap y usos de los mismos.
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.
MX375897B (es) Novedoso anticuerpo anti-presepsina.
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2020013894A (es) Anticuerpos anti-factor xii/xiia y usos de los mismos.
CO2021008755A2 (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
CL2021002075A1 (es) Anticuerpos anti-trem1 y métodos relacionados.
MX2021012652A (es) Metodos para el tratamiento de sujetos con artritis psoriasica.
EA202190698A1 (ru) Гуманизированные анти-c5 антитела и их применение